Earnings per share (EPS) for the three months came in at US$1.41 a share, beating consensus estimates of US$1.39 each.
It also raised its full year outlook for EPS in the range of between US$5.53 and US$5.55 a share compared to between US$5.44 and US$5.54 previously.
The group’s best known drug is the autoimmune drug Humira, which is approved for various conditions including arthritis and Crohn's disease.
It is a major contributor to revenues, which came in at US$7 billion, in line with consensus.
Humira sales came in at $4.7 billion, up 14.8% year over year, excluding the impact of currency.